52505-45-0

Usage

Uses

Used in Organic Synthesis:
2-sulfanylidene-1H-pyridine-3-carbonitrile is used as a key intermediate in the synthesis of various organic compounds due to its unique structural features and reactivity.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-sulfanylidene-1H-pyridine-3-carbonitrile is utilized as a building block for the development of new drugs, given its potential to contribute to the creation of bioactive molecules with therapeutic properties.
Used in Anti-inflammatory Applications:
2-sulfanylidene-1H-pyridine-3-carbonitrile is used as an anti-inflammatory agent for its reported potential to modulate inflammatory processes, offering a promising avenue for the treatment of inflammation-related conditions.
Used in Antioxidant Applications:
As an antioxidant, 2-sulfanylidene-1H-pyridine-3-carbonitrile is employed to neutralize free radicals and protect cells from oxidative damage, which is crucial in the prevention and treatment of various diseases associated with oxidative stress.
Used in Antimicrobial Applications:
In the field of microbiology, 2-sulfanylidene-1H-pyridine-3-carbonitrile is used as an antimicrobial agent, leveraging its potential to inhibit the growth of harmful microorganisms, thereby contributing to the development of new antimicrobial therapies.
Used in Anti-tumor Applications:
2-sulfanylidene-1H-pyridine-3-carbonitrile is studied for its potential anti-tumor activities, making it a candidate for use in oncology research and the development of novel cancer treatments.

InChI:InChI=1/C6H4N2S/c7-4-5-2-1-3-8-6(5)9/h1-3H,(H,8,9)

Upstream product

• 14906-64-0 3-cyanopyridine N-oxide 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 111042-81-0 2-(2-Carbomethoxyethylthio)-3-cyanopyridine 
• 17356-08-0 thiourea 
• 4767-80-0 isothiazolo<4,5-b>pyridine 
• 50-00-0 formaldehyd 
• 7357-70-2 Cyanothioacetamide 
• 75-07-0 acetaldehyde 

Downstream Products

• 91870-91-6 1H-2-methylimidazo<3',4':4,5>thieno<2,3-b>pyridine 
• 55557-48-7 3-Amino-2-carboxamidothieno<2,3-b>pyridine 
• 154237-62-4 2-(4-methylaphenyl)-3-pyridinecarbonitrile 
• 91859-66-4 2-benzylisothiazolo<5,4-b>pyridin-3(2H)-one 
• 4337-60-4 isothiazolo[5,4-b]pyridin-3(2H)-one 
• 52505-47-2 3-aminothieno[2,3-b]pyridine-2-carbonitrile 
• 1620070-38-3 C₃₂H₂₃N₂O₄S^(1-)*Na⁽¹⁺⁾ 

Relevant academic research and scientific papers

Polycyclic N-heterocyclic compounds. Part 84: Reaction of N-(pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-yl)amidines or N-(pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-yl)amidines with hydroxylamine hydrochloride

The reactions of nine N-(pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-yl)amidines (3) with hydroxylamine hydrochloride produced new cyclization products. These were formed via ring cleavage of the pyrimidine component followed by a 1,2,4-oxadiazole-forming r

Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase

Influenza viruses (Flu) are responsible for seasonal epidemics causing high rates of morbidity, which can dramatically increase during severe pandemic outbreaks. Antiviral drugs are an indispensable weapon to treat infected people and reduce the impact on

GLUCOSE UPTAKE INHIBITORS AND USES THEREOF

The present invention relates to novel compounds that modulate cellular glucose uptake by affecting various targets, including, but not limited to those related to glycolysis and known transporters/co-transporters of the GLUT family. The compounds according to the invention are useful for treating cancer such as: neuroendrocrine neoplasms, gastrointestinal stromal tumors (GIST), renal cell carcinoma, paraganglioma, pheochromocytoma, pituitary adenoma, colorectal cancer, lung cancer, gastric cancer, pancreatic cancer sarcoma, head and neck cancer, melanoma, ovarian cancer and other cancers that rely on high levels of glycolysis for survival and proliferation; as well as in treating of autoimmune diseases, inflammation, infectious diseases, and metabolic diseases.

Bioisosteric investigation of ebselen: Synthesis and in vitro characterization of 1,2-benzisothiazol-3(2H)-one derivatives as potent New Delhi metallo-β-lactamase inhibitors

Carbapenem-resistant Enterobacteriaceae (CRE) producing New Delhi metallo-β-lactamase (NDM-1) cause untreatable bacterial infections, posing a significant threat to human health. In the present study, by employing the concept of bioisosteric replacement of the selenium moiety of ebselen, we have designed, synthesized and characterized a small compound library of 2-substituted 1,2-benzisothiazol-3(2H)-one derivatives and related compounds for evaluating their cytotoxicity and synergistic activity in combination with meropenem against the E. coli Tg1 (NDM-1) strain. The most promising compound 3a demonstrated potent synergistic activity against a panel of clinically isolated NDM-1 positive CRE strains with FICI as low as 0.09. Moreover, its IC50 value and inhibition mechanism were also confirmed by using the enzyme inhibition assay and the ESI-MS analysis respectively. Importantly, compound 3a has acceptable toxicity and is not a PAINS. Because of its structural simplicity and potent synergistic activity in combination with meropenem, we propose that compound 3a may be a promising meropenem adjuvant and a new series of such compounds may worth further investigations.

1,2-BENZISOSELENAZOL-3(2H)-ONE AND 1,2-BENZISOTHIAZOL-3(2H)-ONE DERIVATIVES AS BETA-LACTAM ANTIBIOTIC ADJUVANTS

Provided herein are compositions and methods useful in the treatment of beta-lactam antibiotic resistant bacteria.

3-Amino-thieno[2,3-b]pyridines as microtubule-destabilising agents: Molecular modelling and biological evaluation in the sea urchin embryo and human cancer cells

A series of 3-amino-thieno[2,3-b]pyridines was prepared and tested in a phenotypic sea urchin embryo assay to identify potent and specific molecules that affect tubulin dynamics. The most active compounds featured a tricyclic core ring system with a fused cycloheptyl or cyclohexyl substituent and unsubstituted or alkyl-substituted phenyl moiety tethered via a carboxamide. Low nano-molar potency was observed in the sea urchin embryos for the most active compounds (1–5) suggestive of a microtubule-destabilising effect. The molecular modelling studies indicated that the tubulin colchicine site is inhibited, which often leads to microtubule-destabilisation in line with the sea urchin embryo results. Finally, the identified hits displayed a robust growth inhibition (GI50of 50–250?nM) of multidrug-resistant melanoma MDA-MB-435 and breast MDA-MB-468 human cancer cell lines. This work demonstrates that for the thieno[2,3-b]pyridines the most effective mechanism of action is microtubule-destabilisation initiated by binding to the colchicine pocket.

Chemical Inhibition of Human Thymidylate Kinase and Structural Insights into the Phosphate Binding Loop and Ligand-Induced Degradation

Targeting thymidylate kinase (TMPK) that catalyzes the phosphotransfer reaction for formation of dTDP from dTMP is a new strategy for anticancer treatment. This study is to understand the inhibitory mechanism of a previously identified human TMPK (hTMPK) inhibitor YMU1 (1a) by molecular docking, isothermal titration calorimetry, and photoaffinity labeling. The molecular dynamics simulation suggests that 1a prefers binding at the catalytic site of hTMPK, whereas the hTMPK inhibitors that bear pyridino[d]isothiazolone or benzo[d]isothiazolone core structure in lieu of the dimethylpyridine-fused isothiazolone moiety in 1a can have access to both the ATP-binding and catalytic sites. The binding sites of hTMPK inhibitors were validated by photoaffinity labeling and mass spectrometric studies. Taking together, 1a and its analogues stabilize the conformation of ligand-induced degradation (LID) region of hTMPK and block the catalytic site or ATP-binding site, thus attenuating the ATP binding-induced closed conformation that is required for phosphorylation of dTMP.

Thieno[2,3-b]pyridines as negative allosteric modulators of metabotropic GluR5 receptors: Hit-to-lead optimization

An HTS campaign of our corporate compound library resulted in thieno[2,3-b]pyridines derivative hits with mGluR5 negative allosteric modulator effects. During the hit-to-lead development our objective was to improve affinity, and to keep the ligand efficiency values at an acceptable level. After different modifications of the linker resulted in a 2-sulfonyl-thieno[2,3-b] pyridines derivative, which fulfilled the lead criteria.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d] pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors

A useful and rapid access to libraries of N-arylbenzo[b]thieno[3,2-d] pyrimidin-4-amines and their pyrido and pyrazino analogues was designed and optimized for the first time via microwave-accelerated condensation and Dimroth rearrangement of the starting anilines with N′-(2-cyanoaryl)-N,N- dimethylformimidamides obtained by reaction of thiophene precursors with dimethylformamide dimethylacetal. The inhibitory potency of the final products against five protein kinases (CDK5/p25, CK1δ/ε, GSK3α/β, DYRK1A and CLK1) was estimated. N-arylpyrido[3′,2′:4,5]thieno[3,2-d] pyrimidin-4-amine series of compounds (4a-j) turned out to be particularly promising for the development of new pharmacological inhibitors of CK1 and CLK1 kinases.